Differential	O
expression	O
of	O
drug	O
-	O
induced	O
drug	O
targets	O

Integrating	O
4849	O
CMap	O
arrays	O
with	O
40	O
,	O
656	O
drug	O
target	O
relations	O
from	O
STITCH	O
resulted	O
in	O
a	O
set	O
of	O
1	O
,	O
290	O
drug	O
-	O
target	O
relations	O
for	O
which	O
a	O
genome	O
-	O
wide	O
cellular	B-Cell
response	O
is	O
available	O
.	O

We	O
found	O
that	O
thirteen	O
out	O
of	O
167	O
distinct	O
drug	O
targets	O
in	O
this	O
set	O
(	O
8	O
%	O
;	O
86	O
drug	O
target	O
relations	O
)	O
are	O
subjected	O
to	O
significant	O
differential	O
expression	O
upon	O
drug	O
treatment	O
(	O
Figure	O
3	O
)	O
by	O
comparing	O
the	O
drug	O
-	O
induced	O
expression	O
changes	O
of	O
the	O
drug	O
target	O
against	O
all	O
other	O
treatments	O
present	O
in	O
CMap	O
(	O
see	O
methods	O
)	O
.	O

We	O
found	O
supporting	O
evidence	O
in	O
the	O
literature	O
for	O
seven	O
out	O
of	O
thirteen	O
(	O
q	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
significant	O
differential	O
regulations	O
of	O
drug	O
targets	O
shown	O
in	O
Figure	O
3	O
,	O
confirming	O
the	O
rationale	O
and	O
predictive	O
power	O
of	O
our	O
systematic	O
approach	O
.	O

For	O
the	O
remaining	O
six	O
targets	O
we	O
can	O
predict	O
a	O
hitherto	O
unknown	O
drug	O
-	O
induced	O
differential	O
regulation	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pcbi	O
.	O
1000925	O
.	O
g003	O
Figure	O
3	O

Drug	O
-	O
induced	O
differentially	O
regulated	O
drug	O
targets	O
.	O

Anova	O
is	O
used	O
to	O
assess	O
the	O
significance	O
of	O
the	O
differential	O
expression	O
of	O
drug	O
-	O
induced	O
drug	O
targets	O
against	O
the	O
mRNA	O
changes	O
of	O
the	O
same	O
gene	O
in	O
the	O
population	O
of	O
heterogeneous	O
drug	O
treatments	O
from	O
CMap	O
.	O

The	O
genes	O
are	O
mainly	O
ordered	O
based	O
on	O
their	O
q	O
-	O
values	O
as	O
provided	O
in	O
Table	O
S1	O
.	O

In	O
the	O
scatter	O
plots	O
,	O
inhibitors	O
/	O
activators	O
are	O
labeled	O
in	O
red	O
/	O
green	O
respectively	O
and	O
grey	O
represents	O
all	O
other	O
treatments	O
present	O
in	O
CMap	O
.	O

The	O
identified	O
,	O
differentially	O
regulated	O
drug	O
targets	O
are	O
enriched	O
in	O
G	O
-	O
protein	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
(	O
Figure	O
S4	O
)	O
,	O
in	O
agreement	O
with	O
previous	O
reports	O
that	O
members	O
of	O
the	O
GPCR	O
family	O
are	O
generally	O
regulated	O
by	O
several	O
mechanisms	O
including	O
receptor	O
desensitization	O
,	O
endocytosis	O
at	O
the	O
protein	O
level	O
and	O
regulation	O
of	O
the	O
cellular	B-Cell
receptor	O
content	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
.	O

In	O
the	O
three	O
cancer	B-Cell
cell	I-Cell
lines	I-Cell
used	O
,	O
we	O
observe	O
agonist	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
GPCR	O
mRNAs	O
for	O
beta	O
-	O
2	O
adrenergic	O
receptor	O
(	O
ADRB2	O
)	O
,	O
prostaglandin	O
E2	O
receptor	O
subtype	O
EP2	O
and	O
prostaglandin	O
E4	O
receptor	O
subtype	O
EP4	O
(	O
Figure	O
3	O
,	O
Genes	O
3	O
,	O
4	O
,	O
12	O
)	O
,	O
which	O
were	O
previously	O
reported	O
in	O
DDT1	B-Cell
MF	I-Cell
-	I-Cell
2	I-Cell
smooth	I-Cell
muscle	I-Cell
cells	I-Cell
(	O
ADRB2	O
)	O
and	O
293	B-Cell
-	I-Cell
EBNA	I-Cell
human	I-Cell
embryonic	I-Cell
kidney	I-Cell
cells	I-Cell
(	O
prostaglandin	O
E2	O
/	O
E4	O
receptor	O
subtypes	O
EP2	O
/	O
EP4	O
)	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
.	O

This	O
indicates	O
that	O
drugs	O
can	O
induce	O
similar	O
feedback	O
loops	O
in	O
a	O
wide	O
variety	O
of	O
cell	B-Cell
types	O
.	O

However	O
,	O
we	O
cannot	O
rule	O
out	O
that	O
cross	O
-	O
regulation	O
among	O
signaling	O
pathways	O
may	O
be	O
responsible	O
for	O
the	O
regulation	O
of	O
GPCR	O
mRNAs	O
as	O
it	O
has	O
been	O
described	O
before	O
[	O
22	O
]	O
.	O

For	O
example	O
,	O
it	O
has	O
been	O
shown	O
that	O
a	O
beta	O
adrenergic	O
mRNA	O
-	O
binding	O
protein	O
,	O
ELAV	O
-	O
like	O
protein	O
1	O
(	O
ELAVL1	O
)	O
can	O
be	O
induced	O
by	O
ADRB2	O
agonist	O
or	O
elevated	O
levels	O
of	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
[	O
22	O
]	O
,	O
[	O
23	O
]	O
and	O
destabilizes	O
ADRB2	O
mRNA	O
.	O

The	O
ELAVL1	O
protein	O
binds	O
to	O
GPCR	O
mRNAs	O
and	O
recognizes	O
a	O
cognate	O
sequence	O
located	O
at	O
the	O
3	O
'	O
-	O
UTR	O
of	O
ADRB2	O
,	O
proteinase	O
-	O
activated	O
receptor	O
and	O
M2	O
,	O
M3	O
muscarinic	O
acetylcholine	O
receptor	O
mRNAs	O
[	O
24	O
]	O
,	O
[	O
25	O
]	O
.	O

Therefore	O
cAMP	O
provides	O
cross	O
-	O
talk	O
among	O
GPCR	O
regulatory	O
networks	O
.	O

However	O
,	O
it	O
is	O
shown	O
that	O
intracellular	B-Immaterial_anatomical_entity
cAMP	O
accumulation	O
is	O
not	O
the	O
only	O
factor	O
contributing	O
to	O
the	O
reduction	O
of	O
ADRB2	O
mRNA	O
levels	O
[	O
20	O
]	O
.	O

Moreover	O
,	O
we	O
find	O
that	O
GPCR	O
-	O
targeting	O
drugs	O
regulate	O
the	O
transcription	O
of	O
their	O
specific	O
targets	O
(	O
Figure	O
S5	O
)	O
.	O

We	O
conclude	O
that	O
in	O
addition	O
to	O
the	O
cross	O
-	O
regulation	O
of	O
G	O
-	O
protein	O
signaling	O
pathways	O
drug	O
target	O
-	O
specific	O
feedback	O
loops	O
are	O
also	O
responsible	O
for	O
the	O
regulation	O
of	O
drug	O
target	O
mRNAs	O
.	O

In	O
addition	O
to	O
cross	O
-	O
regulation	O
of	O
multiple	O
drugs	O
through	O
the	O
same	O
signaling	O
pathways	O
,	O
promiscuous	O
drugs	O
targeting	O
multiple	O
proteins	O
may	O
cause	O
complex	O
regulatory	O
networks	O
.	O

In	O
order	O
to	O
explore	O
the	O
cross	O
-	O
regulation	O
of	O
drug	O
targets	O
induced	O
by	O
a	O
promiscuous	O
drug	O
,	O
we	O
searched	O
and	O
found	O
that	O
259	O
out	O
of	O
466	O
total	O
drugs	O
are	O
multi	O
-	O
target	O
drugs	O
and	O
4	O
of	O
these	O
drugs	O
act	O
on	O
multiple	O
differentially	O
regulated	O
drug	O
targets	O
upon	O
drug	O
treatment	O
.	O

For	O
example	O
,	O
Podophyllotoxin	O
used	O
in	O
various	O
chemotherapies	O
is	O
known	O
to	O
target	O
both	O
tubulin	O
beta	O
2C	O
and	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
.	O

The	O
tubulin	O
beta	O
2C	O
and	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
mRNAs	O
are	O
both	O
down	O
-	O
regulated	O
upon	O
drug	O
treatment	O
in	O
three	O
cell	B-Cell
lines	I-Cell
(	O
Figure	O
3	O
,	O
Genes	O
8	O
,	O
13	O
)	O
.	O

Tubulin	O
beta	O
2C	O
inhibitors	O
induce	O
microtubule	B-Cellular_component
depolymerization	O
that	O
leads	O
to	O
the	O
specific	O
down	O
-	O
regulation	O
of	O
tubulin	O
beta	O
2C	O
mRNAs	O
preventing	O
the	O
translational	O
synthesis	O
and	O
thus	O
the	O
further	O
accumulation	O
of	O
abundant	O
tubulin	O
monomers	O
[	O
26	O
]	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
mRNAs	O
are	O
not	O
down	O
-	O
regulated	O
upon	O
treatment	O
of	O
other	O
tubulin	O
inhibitors	O
(	O
Figure	O
S5	O
)	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
feedback	O
loops	O
of	O
tubulin	O
beta	O
2C	O
and	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
are	O
not	O
cross	O
-	O
regulated	O
.	O

Two	O
other	O
examples	O
of	O
multi	O
-	O
target	O
drugs	O
are	O
vorinostat	O
used	O
for	O
the	O
treatment	O
of	O
cutaneous	B-Cancer
T	I-Cancer
cell	I-Cancer
lymphoma	I-Cancer
and	O
trichostatin	O
A	O
that	O
serves	O
as	O
an	O
antifungal	O
antibiotic	O
.	O

Vorinostat	O
and	O
trichostatin	O
A	O
are	O
considered	O
to	O
be	O
nonspecific	O
histone	O
deacetylase	O
inhibitors	O
.	O

These	O
drugs	O
lead	O
to	O
the	O
up	O
-	O
regulation	O
of	O
histone	O
deacetylase	O
3	O
(	O
HDAC3	O
)	O
and	O
down	O
-	O
regulation	O
of	O
histone	O
deacetylase	O
7	O
(	O
HDAC7	O
)	O
(	O
Figure	O
3	O
,	O
Genes	O
1	O
,	O
5	O
)	O
.	O

In	O
this	O
case	O
it	O
is	O
unclear	O
whether	O
there	O
is	O
cross	O
-	O
regulation	O
,	O
although	O
HDAC7	O
siRNA	O
experiments	O
failed	O
to	O
induce	O
the	O
up	O
-	O
regulation	O
of	O
HDAC3	O
mRNAs	O
[	O
27	O
]	O
,	O
a	O
result	O
that	O
is	O
disfavoring	O
the	O
cross	O
-	O
regulation	O
.	O

While	O
the	O
above	O
cases	O
only	O
confirm	O
literature	O
reports	O
in	O
other	O
cell	B-Cell
lines	I-Cell
or	O
tissues	B-Tissue
,	O
we	O
also	O
identified	O
new	O
cases	O
of	O
drug	O
-	O
induced	O
expression	O
regulation	O
of	O
drug	O
targets	O
.	O

The	O
significant	O
novel	O
findings	O
are	O
the	O
inhibitor	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
calmodulin	O
1	O
,	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
and	O
up	O
-	O
regulation	O
of	O
endoplasmin	O
,	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
and	O
cAMP	O
-	O
specific	O
phosphodiesterase	O
4D	O
(	O
Figure	O
3	O
,	O
Genes	O
9	O
,	O
8	O
,	O
2	O
,	O
7	O
,	O
10	O
)	O
.	O

Lanosterol	O
14	O
-	O
alpha	O
demethylase	O
is	O
actually	O
an	O
off	O
-	O
target	O
of	O
antifungal	O
drugs	O
that	O
bind	O
the	O
mammalian	O
version	O
with	O
lower	O
affinity	O
than	O
the	O
fungal	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
.	O

Probably	O
,	O
the	O
up	O
-	O
regulation	O
of	O
the	O
mammalian	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
compensates	O
for	O
the	O
undesired	O
inhibition	O
and	O
modulates	O
the	O
adverse	O
effects	O
.	O

On	O
the	O
contrary	O
,	O
we	O
observed	O
a	O
feedback	O
loop	O
that	O
accelerates	O
the	O
down	O
regulation	O
of	O
calmodulin	O
1	O
mRNA	O
induced	O
by	O
calmodulin	O
inhibitors	O
.	O

Calmodulin	O
targeting	O
drugs	O
can	O
provide	O
a	O
rapid	O
and	O
effective	O
therapeutic	O
effect	O
,	O
while	O
at	O
the	O
same	O
time	O
small	O
variations	O
of	O
drug	O
concentrations	O
can	O
increase	O
adverse	O
effects	O
.	O

Therefore	O
,	O
it	O
would	O
be	O
interesting	O
to	O
study	O
further	O
the	O
functional	O
effects	O
upon	O
target	O
inhibition	O
of	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
,	O
endoplasmin	O
and	O
calmodulin	O
1	O
to	O
elucidate	O
the	O
roles	O
of	O
feedback	O
loops	O
in	O
drug	O
mode	O
of	O
action	O
and	O
adverse	O
effects	O
.	O

Drug	O
-	O
induced	O
target	O
regulation	O
might	O
be	O
implicated	O
in	O
tolerance	O
development	O
and	O
thus	O
identifying	O
potential	O
target	O
regulation	O
should	O
be	O
an	O
integral	O
part	O
of	O
drug	O
discovery	O
to	O
prevent	O
failures	O
in	O
later	O
stages	O
of	O
clinical	O
trials	O
.	O

For	O
example	O
,	O
we	O
have	O
observed	O
the	O
inhibitor	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
ADRB2	O
and	O
thymidylate	O
synthetase	O
(	O
TYMS	O
)	O
(	O
Figure	O
3	O
,	O
Genes	O
3	O
,	O
11	O
)	O
[	O
28	O
]	O
.	O

TYMS	O
is	O
an	O
essential	O
enzyme	O
for	O
DNA	O
replication	O
/	O
repair	O
and	O
an	O
important	O
drug	O
target	O
in	O
cancerous	B-Cell
cells	I-Cell
.	O

Indeed	O
,	O
it	O
has	O
been	O
shown	O
that	O
inhibitor	O
-	O
induced	O
TYMS	O
over	O
-	O
expression	O
obstructs	O
the	O
clinical	O
efficiency	O
by	O
inducing	O
tumor	B-Cancer
drug	O
resistance	O
[	O
29	O
]	O
.	O

In	O
addition	O
to	O
over	O
-	O
expression	O
,	O
down	O
-	O
regulation	O
of	O
drug	O
targets	O
upon	O
agonist	O
treatment	O
may	O
also	O
cause	O
treatment	O
tolerance	O
as	O
observed	O
for	O
ADRB2	O
long	O
-	O
acting	O
agonist	O
treatment	O
.	O

ADRB2	O
is	O
a	O
therapeutic	O
target	O
activated	O
to	O
treat	O
the	O
symptoms	O
of	O
asthma	O
.	O

We	O
observe	O
the	O
agonist	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
ADRB2	O
and	O
already	O
in	O
2005	O
,	O
the	O
FDA	O
warned	O
patients	O
that	O
ADRB2	O
might	O
be	O
down	O
-	O
regulated	O
(	O
desensitization	O
)	O
and	O
be	O
unresponsive	O
for	O
asthma	O
treatment	O
due	O
to	O
long	O
-	O
acting	O
agonist	O
exposure	O
[	O
20	O
]	O
,	O
[	O
30	O
]	O
.	O

Thus	O
,	O
robustness	O
in	O
biological	O
systems	O
could	O
prevent	O
the	O
applicability	O
of	O
the	O
long	O
-	O
term	O
treatments	O
via	O
positive	O
/	O
negative	O
feedback	O
loops	O
of	O
the	O
drug	O
target	O
affecting	O
the	O
clinical	O
efficiency	O
of	O
drugs	O
in	O
trial	O
and	O
on	O
the	O
market	O
.	O

Drug	O
-	O
induced	O
regulation	O
of	O
drug	O
targets	O
can	O
thus	O
be	O
linked	O
to	O
tolerance	O
development	O
,	O
which	O
restricts	O
the	O
efficiency	O
of	O
clinical	O
treatments	O
where	O
the	O
drug	O
concentration	O
is	O
limited	O
to	O
avoid	O
an	O
excess	O
of	O
adverse	O
drug	O
reactions	O
.	O

Taken	O
together	O
,	O
we	O
have	O
identified	O
drug	O
-	O
induced	O
differential	O
regulation	O
of	O
drug	O
targets	O
.	O

Due	O
to	O
the	O
limited	O
signal	O
to	O
noise	O
ratio	O
in	O
the	O
data	O
at	O
hand	O
,	O
the	O
identified	O
8	O
%	O
of	O
all	O
drug	O
targets	O
that	O
show	O
feedback	O
loops	O
has	O
to	O
be	O
seen	O
as	O
a	O
lower	O
limit	O
,	O
i	O
.	O
e	O
.	O
target	O
-	O
regulation	O
appears	O
as	O
a	O
wide	O
-	O
spread	O
biological	O
phenomenon	O
that	O
has	O
to	O
be	O
taken	O
into	O
account	O
during	O
drug	O
development	O
.	O

